This content is in French.
NIAGARA: A Wave of Hope for Invasive Bladder Cancer
6 février 2025

#Oncology #MIBC #Immunotherapy #Chemotherapy #NIAGARA #CombinationTherapy #PersonalizedMedicine
Muscle-invasive bladder cancer (MIBC) is an aggressive form of urothelial carcinoma characterized by invasion into the bladder muscle layer. Associated with a high risk of metastatic progression and recurrence, this condition has a low five-year survival rate, particularly when diagnosed at an advanced stage.
The survival rate is further compromised by the limitations of current treatments—cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy. These treatments are often hindered by tumor resistance and treatment inadequacy. In response to these challenges, the hypothesis of a combined therapy integrating conventional chemotherapy with targeted immunotherapy has emerged as a promising solution. This strategy aims to harness anti-tumor immunity to enhance tumor responses.
Muscle-invasive bladder cancer (MIBC) is an aggressive form of urothelial carcinoma characterized by invasion into the bladder muscle layer. Associated with a high risk of metastatic progression and recurrence, this condition has a low five-year survival rate, particularly when diagnosed at an advanced stage.
The survival rate is further compromised by the limitations of current treatments—cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy. These treatments are often hindered by tumor resistance and treatment inadequacy. In response to these challenges, the hypothesis of a combined therapy integrating conventional chemotherapy with targeted immunotherapy has emerged as a promising solution. This strategy aims to harness anti-tumor immunity to enhance tumor responses.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Saylor, B. (2024). NIAGARA: Durvalumab plus chemo improves EFS and OS in cisplatin-eligible MIBC
View the source


